453 related articles for article (PubMed ID: 15817597)
21. Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer.
Bajetta E; Celio L; Ferrario E; Di Bartolomeo M; Denaro A; Dotti K; Mancin M; Bajetta R; Colombo A; Pusceddu S
Ann Oncol; 2007 Nov; 18(11):1810-6. PubMed ID: 17823385
[TBL] [Abstract][Full Text] [Related]
22. Weekly High-dose 5-Fluorouracil as 24-hour Infusion Combined with Sodium Folinic Acid (AIO regimen) Plus Irinotecan in Second-line and Sequential Therapy of Metastatic Colorectal Cancer (CRC).
Wein A; Siebler J; Wolff K; Ostermeier N; Busse D; Hagel A; Koch F; Merx K; Neurath MF; Hofheinz RD
Anticancer Res; 2017 Jul; 37(7):3771-3779. PubMed ID: 28668873
[TBL] [Abstract][Full Text] [Related]
23. Phase I dose-escalation trial of irinotecan with continuous infusion 5-FU first line, in metastatic colorectal cancer.
Saunders MP; Hogg M; Carrington B; Sjursen AM; Allen J; Beech J; Swindell R; Valle JW
Br J Cancer; 2004 Oct; 91(8):1447-52. PubMed ID: 15452550
[TBL] [Abstract][Full Text] [Related]
24. Biweekly oxaliplatin plus irinotecan and folinic acid-modulated 5-fluorouracil: a phase II study in pretreated patients with metastatic colorectal cancer.
Comella P; Massidda B; Palmeri S; Putzu C; De Rosa V; Izzo F; Fiore F; Casaretti R; Sandomenico C
Anticancer Drugs; 2006 Sep; 17(8):985-92. PubMed ID: 16940809
[TBL] [Abstract][Full Text] [Related]
25. Concurrent irinotecan and 5-fluorouracil plus levo-folinic acid given every other week in the first-line management of advanced colorectal carcinoma: a phase I study of the Southern Italy Cooperative Oncology Group.
Comella P; Casaretti R; De Vita F; Avallone A; Orditura M; Petrillo A; Gravina A; Faranda A; Comis S; Comella G; Catalano G
Ann Oncol; 1999 Aug; 10(8):915-21. PubMed ID: 10509152
[TBL] [Abstract][Full Text] [Related]
26. Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors.
Goetz MP; Erlichman C; Windebank AJ; Reid JM; Sloan JA; Atherton P; Adjei AA; Rubin J; Pitot H; Galanis E; Ames MM; Goldberg RM
J Clin Oncol; 2003 Oct; 21(20):3761-9. PubMed ID: 12963697
[TBL] [Abstract][Full Text] [Related]
27. Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study.
Kwon HC; Oh SY; Lee S; Kim SH; Kim HJ
World J Gastroenterol; 2007 Dec; 13(46):6231-5. PubMed ID: 18069765
[TBL] [Abstract][Full Text] [Related]
28. Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patients.
Bécouarn Y; Gamelin E; Coudert B; Négrier S; Pierga JY; Raoul JL; Provençal J; Rixe O; Krisch C; Germa C; Bekradda M; Mignard D; Mousseau M
J Clin Oncol; 2001 Nov; 19(22):4195-201. PubMed ID: 11709562
[TBL] [Abstract][Full Text] [Related]
29. A phase II study of irinotecan alternated with five days bolus of 5-fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cancer.
Van Cutsem E; Pozzo C; Starkhammar H; Dirix L; Terzoli E; Cognetti F; Humblet Y; Garufi C; Filez L; Gruia G; Cote C; Barone C
Ann Oncol; 1998 Nov; 9(11):1199-204. PubMed ID: 9862050
[TBL] [Abstract][Full Text] [Related]
30. Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study.
Santini D; Vincenzi B; Schiavon G; Di Seri M; Virzí V; Spalletta B; Caricato M; Coppola R; Tonini G
Cancer Chemother Pharmacol; 2007 Apr; 59(5):613-20. PubMed ID: 16944151
[TBL] [Abstract][Full Text] [Related]
31. A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy.
Hecht JR; Pillai M; Gollard R; Heim W; Swan F; Patel R; Dreiling L; Mo M; Malik I
Clin Colorectal Cancer; 2010 Apr; 9(2):95-101. PubMed ID: 20378503
[TBL] [Abstract][Full Text] [Related]
32. Dose escalating clinical study of high dose infusional 5-fluorouracil and leukovorin (AIO regimen) plus alternate weekly administration of oxaliplatin and irinotecan in patients with advanced tumors of the gastrointestinal tract.
Gkioulbasanis I; Souglakos J; Vardakis N; Kotsakis A; Saridaki Z; Kentepozidis N; Polyzos A; Giassas S; Ignatiadis M; Bozionelou V; Christophylakis C; Georgoulias V
J BUON; 2007; 12(2):197-202. PubMed ID: 17600872
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H
Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736
[TBL] [Abstract][Full Text] [Related]
34. A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only.
Bendell JC; Zakari A; Peyton JD; Boccia R; Moskowitz M; Gian V; Lipman A; Waterhouse D; LoCicero R; Earwood C; Lane CM; Meluch A
Oncologist; 2016 Mar; 21(3):279-80. PubMed ID: 26911408
[TBL] [Abstract][Full Text] [Related]
35. Phase I/II study of irinotecan, 5-fluorouracil, and l-leucovorin combination therapy (modified Saltz regimen) in patients with metastatic colorectal cancer.
Goto A; Yamada Y; Hosokawa A; Ura T; Arai T; Hamaguchi T; Muro K; Shimada Y; Shirao K
Int J Clin Oncol; 2004 Oct; 9(5):364-8. PubMed ID: 15549585
[TBL] [Abstract][Full Text] [Related]
36. A multicenter phase II study of irinotecan (CPT-11) alternated with 5-fluorouracil and leucovorin as first-line treatment of patients with metastatic colorectal cancer.
Reina JJ; Aparicio J; Salvador J; Pica JM; Rueda A; Lorenzo A; de la Puente CG; Borrega P; Moreno-Nogueira JA
Cancer Chemother Pharmacol; 2003 Oct; 52(4):339-45. PubMed ID: 12851783
[TBL] [Abstract][Full Text] [Related]
37. [Phase I study of CPT-11 and continuous 5-FU / l-leucovorin combination therapy(modified AIO regimen)in patients with metastatic colorectal cancer].
Nakamura T; Kurachi K; Fukazawa A; Hayashi T; Nakamura K; Nakajima A; Suzuki S; Konno H
Gan To Kagaku Ryoho; 2008 Oct; 35(10):1697-701. PubMed ID: 18931571
[TBL] [Abstract][Full Text] [Related]
38. Weekly high-dose 5-fluorouracil as 24-h infusion and folinic acid (AIO) plus irinotecan as second- and third-line treatment in patients with colorectal cancer pre-treated with AIO plus oxaliplatin.
Stickel F; Jüngert B; Brueckl V; Schirner I; Brueckl WM; Männlein G; Hegewald J; Mühldorfer S; Bittorf B; Hohenberger W; Hahn EG; Wein A
Anticancer Drugs; 2003 Oct; 14(9):745-9. PubMed ID: 14551509
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and tolerability of oxaliplatin plus irinotecan 5-fluouracil and leucovorin regimen in advanced stage colorectal cancer patients pretreated with irinotecan 5-fluouracil and leucovorin.
Stathopoulos GP; Rigatos SK; Stathopoulos JG; Xynotroulas JP; Dimou E
Am J Clin Oncol; 2005 Dec; 28(6):565-9. PubMed ID: 16317265
[TBL] [Abstract][Full Text] [Related]
40. High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7).
Maindrault-Goebel F; de Gramont A; Louvet C; André T; Carola E; Mabro M; Artru P; Gilles V; Lotz JP; Izrael V; Krulik M;
Eur J Cancer; 2001 May; 37(8):1000-5. PubMed ID: 11334725
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
